Xiao Xu

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, EBioMedicine.

Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance

Xiao Dong Xu, Xiao Xu, 2015, Chinese journal of cancer.

First‐in‐Human Phase I Study of AC0010, a Mutant‐Selective EGFR Inhibitor in Non–Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance

Yang Zhang, Ji Jiang, P. Hu, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy

Dahai Zhao, Jian Feng, Zhengrong Zhang, 2021, Frontiers in Oncology.

Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC).

Ying Cheng, Yi-long Wu, B. Han, 2019, Journal of Clinical Oncology.

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study

Ying Cheng, Yi-long Wu, B. Han, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.